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Abstract
Mechanical circulatory assist devices are now commonly used in the treatment of severe heart failure as bridges to
cardiac transplant, as destination therapy for patients who are not transplant candidates, and as bridges to recovery
and “decision-making”. These devices, which can be used to support the left or right ventricles or both, restore
circulation to the tissues, thereby improving organ function. Left ventricular assist devices (LVADs) are the most
common support devices. To care for patients with these devices, health care providers in emergency departments
(EDs) and intensive care units (ICUs) need to understand the physiology of the devices, the vocabulary of
mechanical support, the types of complications patients may have, diagnostic techniques, and decision-making
regarding treatment. Patients with LVADs who come to the ED or are admitted to the ICU usually have nonspecific
clinical symptoms, most commonly shortness of breath, hypotension, anemia, chest pain, syncope, hemoptysis,
gastrointestinal bleeding, jaundice, fever, oliguria and hematuria, altered mental status, headache, seizure, and back
pain. Other patients are seen for cardiac arrest, psychiatric issues, sequelae of noncardiac surgery, and trauma.
Although most patients have LVADs, some may have biventricular support devices or total artificial hearts. Involving
a team of cardiac surgeons, perfusion experts, and heart-failure physicians, as well as ED and ICU physicians and
nurses, is critical for managing treatment for these patients and for successful outcomes. This review is designed for
critical care providers who may be the first to see these patients in the ED or ICU.
Keywords: Biventricular assist device, Cardiac arrest, Device failure, Gastrointestinal bleeding, Hemodynamic,
Hypotension, Mechanical circulatory assist devices, Sepsis, Shortness of breath, Total artificial heart
Background
Mechanical circulatory assist devices are now commonly
used to support the failing heart: as a bridge to transplant
(BTT) to support cardiac function before heart transplant-
ation; as a bridge to recovery to give the native heart a
chance to recover; as a bridge to decision until a deter-
mination can be made regarding a patient’s eligibility for
cardiac transplantation; as a bridge until a more definitive
device can be implanted (e.g., a biventricular assist device
[BiVAD] to a left ventricular assist device [LVAD]); and as
destination therapy (DT) to support cardiac function for
the remainder of a patient’s life [1, 2].
Mechanical circulatory assist devices restore tissue cir-
culation by increasing blood supply, thereby improving
organ function. However, they can be challenging to
manage and are associated with complications, some of
which are life-threatening. With increasing numbers of
devices being implanted both for BTT and for DT, crit-
ical care and emergency physicians should become fa-
miliar with the different types of devices (Fig. 1) [3, 4],
understand the unique physiology associated with them,
be familiar with the clinical presentation of patients who
experience complications, and know how to manage
symptoms and complications.
Device descriptions
Depending upon the indication, one of the following
types of devices, often called pumps, may be implanted:
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paracorporeal or extracorporeal devices, which are placed
outside the patient’s body, and intracorporeal devices,
which are implanted in a preperitoneal position either
above (in the pericardial space) or below the diaphragm
(Fig. 2). All of the currently available implantable pumps
have external controllers and power sources. Of the im-
plantable devices, LVADs, as the name suggests, support
left ventricular (LV) function in a situation where right
ventricular (RV) function is adequate and RV assist de-
vices (RVADs) support right ventricular function when LV
function is adequate. For patients who require both RV
and LV support, a BiVAD configuration can be used.
BiVADs are composed of two separate devices: one for
support of the RV and one for support of the LV. For pa-
tients with little remaining native cardiac function and no
hope for a recovery, a total artificial heart (TAH) may be
the only option. TAHs replace all functions of the native
heart.
Blood-flow characteristics
Mechanical circulatory assist devices produce either
pulsatile or continuous blood flow. The first LVADs
were pulsatile or displacement (pusher-plate) pumps.
These devices were too large for an average-sized per-
son, had a number of parts that could fail (e.g., valves,
inflow and outflow conduits), and were associated with
a variety of complications. They have been replaced
with a new generation of continuous-flow pumps,
which have inlet and outlet ports and a single, rotating
element that imparts energy to the blood to increase ar-
terial blood flow and pressure [5]. Blood is pulled into
the impeller of the pump via an inflow cannula con-
nected to the LV apex and delivered to the systemic cir-
culation via an outflow cannula connected to either the
ascending or descending aorta. Because the continuous-
flow pumps have few moving parts, when properly
functioning they seldom fail and are also associated
Fig. 1 Classification of mechanical circulatory support devices. BiVAD biventricular assist device, ECMO extracorporeal membrane oxygenation,
LVAD left ventricular assist device, PVAD pulsatile ventricular assist device, RVAD right ventricular assist device, VAD ventricular assist device. BVS
5000 (Abiomed Inc.), CentriMag (Thoratec Corp.), EvaHeart (Evaheart, Inc. [available in Japan]), HeartAssist5 (ReliantHeart [CE mark in Europe, FDA
approval for humanitarian device exception in the United States for pediatric patients]), HeartMate II (Thoratec Corp.), HeartWare HVAD (HeartWare
Inc.), Impella (Abiomed Inc.), Incor (Berlin Heart AG [available in Europe]), Jarvik 2000 (Jarvik Heart, Inc.), Rotaflow (Maquet Holding BV & Co.),
TandemHeart (CardiacAssist, Inc), VentriAssist (Ventracor, Ltd [available in Australia])
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with fewer complications than their predecessors, which
has improved the quality of life for BTT and DT pa-
tients [6–8].
Continuous-flow LVADs available today produce two
types of blood flow: centrifugal or axial [9]. In a centrifu-
gal pump, blood is captured between rotating blades,
Fig. 2 Most commonly used mechanical circulatory support devices. a The HeartMate II LVAD (Thoratec Corp.). b The HeartWare LVAD
(HeartWare Inc.). c The SynCardia TAH (left) shown for comparison with the human heart (right) (SynCardia Systems, Inc.). LVAD left ventricular
assist device, TAH total artificial heart. a From Mayo Foundation for Medical Education and Research; used with permission. b Provided by
HeartWare; used with permission. c Image courtesy of syncardia.com; used with permission
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which spin and, basically, throw the blood tangentially
out from the blade tips (an induced force). In an axial-
flow device, the rotating impeller operates like a propel-
ler in a pipe. This mechanism can be thought of as an
auger, trying to screw itself into the blood coming
through the inlet cannula against the resistance force at
the outlet cannula to overcome the difference between
preload and afterload (Fig. 3). The two most commonly
used devices today are the HeartMate II (Thoratec
Corp.), an axial-flow device, and the HeartWare HVAD
System (HeartWare Inc.), a centrifugal-flow device.
Definitions
The following selected definitions are important to
the understanding of how mechanical support devices
operate.
RPM
The revolutions per minute (RPMs), which determine
pump flow, are set for each device by the heart failure
physician caring for the patient. They are modified as
flow needs change.
Flow
The continuous flow from the LVAD is created by a spin-
ning impeller, which generates forward flow [10]. A
change in pump function or patient condition leads to
changes in flow. The device flow is directly proportional
to the rotor speed and inversely related to the difference
of pressure in the inflow and outflow cannulas, i.e., Device
flow = Rotor speed/(Pumpinflow − Pumpoutflow). Therefore,
in addition to low RPM rate, a low flow rate could be
caused by a number of conditions that would decrease
preload to the device, such as decreased intravascular vol-
ume, RV failure, tamponade, thrombus, or kinking in the
inflow cannula. In addition, low flow can occur with high
afterload, such as when a patient has a hypertensive emer-
gency or when the outflow cannula is obstructed.
Pump power
LVAD pump power is a measure of the current and volt-
age applied to the motor and varies directly with pump
speed and flow [10]. When flow is obstructed unrelated
to contact with the rotor, power is reduced, whereas
power is increased (and flows decreased) when thrombus
forms on the rotor.
Pulsatility index
The pulsatility index (PI) corresponds to the magnitude
of flow pulse through the pump. The magnitude of flow
pulse is measured and averaged over a 15-s interval to
produce the PI for the HeartMate II (but not the Heart-
Ware) [11]. The PI fluctuates with changes in volume
status and the heart’s contractility. It increases when pre-
load and contractility increase and decreases when blood
volume and afterload are reduced and when there is an
obstruction to inflow or outflow that causes low flow
and abnormal power.
Suction events
A suction event occurs when there is reduced filling of
the pump (reduced preload), which increases negative
pressure within the LV. When this occurs, part of the
LV wall is sucked over and covers the pump’s inlet can-
nula; the pump then sounds an alarm and the speed will
decrease to release the suction. Suction events are
caused by low volume; RV failure or tamponade, which
causes low LV filling; and inflow cannula obstruction.
Suction events can lead to low LVAD flows and can trig-
ger ventricular arrhythmias. The management includes
decreasing the RPM rate and administering fluid [10].
Abnormal LVAD parameters and their diagnosis and
management are listed in Table 1.
Fig. 3 a Axial blood flow, shown in the HeartMate II LVAD (Thoratec Corp.). b Centrifugal blood flow, shown in the HeartWare LVAD (HeartWare
Inc.). a Reprinted with the permission of Thoratech Corp. b Provided by HeartWare; used with permission
Sen et al. Critical Care  (2016) 20:153 Page 4 of 20
Modes
Two modes can be set for the HeartMate II: fixed and
auto. In fixed-rate mode, the pump rate is set close to
the patient’s baseline value and does not vary, although
the rate can be adjusted by using the system monitor. In
auto mode, the LVAD responds to the patient’s activity
and volume status, filling and emptying as needed to
meet physiologic demand.
Clinical presentations of patients with LVADs
Patients with LVADs who come to the emergency de-
partment (ED) or are admitted to the intensive care
unit (ICU) usually have symptoms but not a clinical
diagnosis. The following review will hopefully direct
the provider in an ED or critical care unit to an ap-
proach for a differential diagnosis of symptoms for
ventricular assist device (VAD)-specific and non-VAD-
specific causes. Although this primer is meant for
providers who see patients in an emergency setting,
the approaches are also relevant for diagnosing and
treating patients with new LVADs in a postoperative
setting.
The common symptoms of patients with LVADs
are nonspecific and include shortness of breath, hypo-
tension, anemia, chest pain, syncope, hemoptysis, nau-
sea, vomiting, diarrhea, gastrointestinal (GI) bleeding,
jaundice, fever, chills, oliguria and hematuria, altered
mental status, headache, seizure, and back pain. Other
patients are seen for cardiac arrest, psychiatric issues,
sequelae of noncardiac surgery, issues related to preg-
nancy, and trauma. The critical care physician may
also need to evaluate patients for brain death and
organ donation.
Symptom approach
The following section describes a symptom-oriented
approach for critical care providers to use in deter-
mining differential diagnoses and treating patients
with LVADs.
Shortness of breath
Shortness of breath (dyspnea or tachypnea) in an LVAD
patient can be caused by the following three pathophysi-
ologic conditions: reduced oxygen delivery, increased
oxygen consumption, and inadequate carbon dioxide
exchange. Causes of reduced oxygen delivery include
hypoxic respiratory failure, acute anemia, and reduced
cardiac output (CO). Increased oxygen consumption
may be caused by adrenergic stress or vasodilation due
to sepsis, anaphylaxis, acidosis, adrenal insufficiency, or
liver dysfunction. Inadequate carbon dioxide exchange
may be due to neurologic causes; neuromuscular issues;
extrinsic causes, such as ascites; ileus; or reduced blood
flow through pulmonary capillaries, such as in shock.
Patients who have shortness of breath should have
their arterial blood gas and lactate levels measured,
should be monitored with continuous pulse oximetry
(although this may not be accurate because of continu-
ous flow), and have a chest radiograph and, if necessary,
a computed tomography (CT) scan. Supplemental oxy-
gen (i.e., nasal cannula, face mask, high-flow oxygen,
noninvasive positive-pressure ventilation, or mechanical
ventilation) should be used according to the usual stand-
ard of care. When acute hypoxic respiratory failure is
the cause of shortness of breath, it may be helpful to as-
sess the effect of an increased fraction of inspired oxygen
(FIO2), which will improve dead space versus increased
Table 1 Diagnosis and management of abnormal LVAD parameters
Abnormality Cause Interventions
High power Pump thrombus Anticoagulation therapy, pump exchange
Low power Device problem Check batteries, power source
High pulsatility index Recovery of LV function Wean LVAD support
Lead damage Check LVAD and driveline
Low pulsatility index Worsening native ventricular function Increase pump speed, inotropic therapy
Hypovolemia Administer fluid therapy
Excess pump speed Lower pump speed
High flow rate Vasodilation (SALAD [sepsis/anaphylaxis/liver dysfunction/adrenal
insufficiency/medications])
Identify and treat causes of sepsis; administer
vasopressors for low mean arterial pressure
Low flow rate Hypovolemia/bleeding RV failure/tamponade/hypertensive emergency Administer intravenous fluids/blood
Assess and treat
Arrhythmias Assess and treat
Suction events All causes of low flow Administer fluid therapy
Excessive LV unloading Lower pump speed
LV left ventricular, LVAD left ventricular assist device, RV right ventricular. Adapted from Feldman et al. [8] with permission
Sen et al. Critical Care  (2016) 20:153 Page 5 of 20
positive end-expiratory pressure (PEEP), which will im-
prove a pulmonary shunt. If neither increased FIO2 nor
PEEP improves oxygenation, a cardiac shunt, such as an
open patent foramen ovale, may be the cause and should
be considered in the diagnosis of the shortness of breath.
The patient’s hematocrit and hemoglobin levels should
be assessed to rule out bleeding and hemolysis as causes
of shortness of breath. Patients with LVADs take antic-
oagulation medications and have a bleeding diathesis in
addition to the risk of hemolysis from the device–blood
interaction.
Reduced CO may also cause shortness of breath. Car-
diogenic Shock needs to be considered in the differential
diagnosis. These patients may also have co-existent
hypotension (see the “Shock” section below for the ap-
proach to management of this condition).
The patient should be intubated for mechanical venti-
lation when hypoxia, hypercarbia, or acidosis worsens or
when the airway cannot be protected. Rapid sequence
intubation should be performed. Any anesthetic induction
agent can be considered, although etomidate or a narcotic
and benzodiazepine combination like fentanyl plus mid-
azolam is often preferred. Lung-protective ventilation strat-
egies which include a low tidal volume (VT) and adequate
PEEP should be used. A very high PEEP can cause worsen-
ing of RV dysfunction and should be avoided. Therapeutic
management may include draining a pleural effusion,
inserting a chest tube for pneumothorax, performing a
bronchoscopy procedure, and optimizing hemodynamics.
Shock
Shock (or hypotension) is defined as mean arterial pres-
sure less than 60 mmHg, as measured by Doppler ultra-
sonography. Figure 4 summarizes making the differential
diagnosis and the approach to treating LVAD patients
who have hypotension. As in patients without LVADs,
hypotension can be due to hypovolemia (often caused by
hemorrhage), cardiogenic shock (often obstructive shock),
Fig. 4 Differential diagnosis and management of hypotension and shock in patients with LVADs. CRT capillary refill time, CVP central venous
pressure, echo echocardiography, IV intravenous, IVC inferior vena cava, LV left ventricular, MI myocardial infarction, PA pulmonary artery, PAC
pulmonary artery catheter, PLR passive leg raising, RV right ventricle, SVO2 mixed venous oxygen saturation, UOP urinary output, VAD ventricular
assist device
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or systemic vasodilation and the clinical examination may
help determine the cause. Assessing the extremities (i.e.,
warm or cold) is critical to the diagnosis. Cold and mot-
tled extremities indicate cardiogenic (obstructive) or hypo-
volemic (hemorrhagic) shock and patients with these
conditions may also have reduced urine output, altered
mental status, tachycardia, and shortness of breath.
The LVAD flow rate must also be assessed. An arterial
catheter should be inserted for continuous mean arterial
pressure (MAP) monitoring and is best placed via ultra-
sonographic guidance (continuous flow makes blind
placement difficult). In addition, a central venous cath-
eter may be needed to assess central venous pressure,
preload, and preload responsiveness.
Bedside cardiac ultrasonography is very helpful for
assessing hemodynamic parameters in a patient with an
LVAD, especially when echocardiography has not been
completed; it can be used for the following:
 Inferior vena cava and collapsibility
 RV size and function
 Position of the ventricular septum (flat and neutral)
 LV size and function
 Signs of pericardial effusion or tamponade
 Inflow cannula (if visualized) aligned with the mitral
valve
 Outflow cannula (if visualized)
 Competency of the aortic valve (it should be
competent and open intermittently, every second or
third beat).
Cardiogenic and obstructive shock
Patients with LVADs can have cardiogenic or obstructive
shock with acute heart failure and hemodynamic instabil-
ity because of device malfunction or new cardiovascular
dysfunction that is refractory to supportive therapy. These
patients may require temporary circulatory support, either
with an intraaortic balloon pump, a percutaneous LVAD
(i.e., TandemHeart [CardiacAssist, Inc.]), or venoarterial
extracorporeal membrane oxygenation.
The causes of cardiogenic shock and reduced CO,
which cause hypotension in patients with LVADs, follow.
New-onset LV dysfunction
New-onset LV dysfunction may manifest as fluid overload
or other signs of cardiogenic shock, such as cold, clammy
extremities, altered mental status, shortness of breath, and
reduced urine output. The cause of the dysfunction may
be a new myocardial infarction (MI), arrhythmias, aortic
valve degeneration causing aortic regurgitation, pericardial
tamponade, or decreased LV function because of worsen-
ing contractility and fluid overload, or both. Management
includes adjusting the LVAD speed, use of inotropic,
diuretic, and antiarrhythmic agents, relieving tamponade,
if present, and consideration of percutaneous LV support.
Patients with LVADs can have an acute MI from rupture
of a coronary plaque or from paradoxical thromboembol-
ism from a deep venous thrombosis, thromboembolism
from an intracavitary thrombus in the LV or from the aor-
tic root, and device failure, which leads to elevated LV fill-
ing pressures and impaired myocardial perfusion [12].
However, LV catheterization should be performed only
after carefully weighing the risks and potential benefits to
the patient. The potential benefits of a coronary interven-
tion include (1) relieving symptoms, (2) preventing and
treating of recurrent arrhythmias, (3) reducing ongoing
myocardial damage, (4) supporting RV function if RV fail-
ure is present, and (5) avoiding LVAD alarms [13–15].
The potential disadvantages of cardiac catheterization are
aortic valve or root thrombosis and wire entrapment in
the inflow or outflow pump conduits or rotor [12].
RV failure
RV failure can occur in 5 to 10 % of patients after an
LVAD implantation [16]. Echocardiographic parameters
suggestive of RV failure include RV dilatation, reduced
RV ejection fraction, reduced excursion of the tricuspid
annulus as assessed on tissue Doppler imaging, and tri-
cuspid regurgitation [12, 17]. Hemodynamic variables
consistent with RV failure for a patient supported by an
LVAD include a central venous pressure of more than
15 mmHg. If a pulmonary artery catheter is placed, it
may show an elevated, mean pulmonary artery pressure
greater than 25 mmHg and a high central venous pressure
greater than 15 mmHg, with normal-to-low pulmonary
capillary wedge pressure. Therefore, it is important to
maintain RV function and reduce preload and afterload.
Several approaches are used to help maintain RV func-
tion. A low dose of an inotropic agent, such as dobuta-
mine, epinephrine, or milrinone, is routinely administered
and, when necessary, a vasoconstrictor agent is also ad-
ministered (both support MAP). The ventricular septum
should be maintained in a neutral position to avoid left-
ward or rightward shift, which can lead to a suction event.
Maintaining the septum in its normal position can be
done by carefully monitoring fluid volume, inotropes, and
device settings and can be assessed by echocardiography.
Too high a flow will shift the septum leftward and impair
RV function; too low a flow will shift the septum right-
ward and cause increased left atrial pressure, which
impairs RV function [18]. Anything that might cause pul-
monary vascular resistance to increase, such as hypercar-
bia and hypoxia or high ventilation pressures or levels of
PEEP, also needs to be controlled. Impaired RV function
and increased pulmonary vascular resistance can be
treated by giving sildenafil (25–50 mg every 8 h) or in-
haled nitric oxide (20–40 ppm). In addition, the MAP
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should be maintained at a level higher than 60–70 mmHg
to help maintain RV perfusion pressure. Volume adminis-
tration needs to be controlled to avoid increased right
ventricular end- diastolic pressure.
A central venous pressure greater than 18 mmHg in
association with a cardiac index less than 2.0 L/min/m2
despite optimal medical therapy indicates the need for
RVAD support. Either the Impella RP (Abiomed) or the
TandemHeart (CardiacAssist, Inc.) right ventricular sup-
port device can be used for short-term percutaneous
mechanical support until recovery of myocardial func-
tion or as a bridge to an RVAD [19].
Cardiac tamponade and tension pneumothorax
Hypotension and low device flow rates (whether or not
suction events exist) may indicate developing cardiac
tamponade, which can occur late. Bleeding diathesis and
anticoagulation therapy are risk factors for tamponade.
An urgent bedside echocardiogram may show the cause
of the tamponade; however, transesophageal echocardi-
ography (TEE) may be necessary for the diagnosis (e.g.,
when the windows on surface echocardiography are
poor and unrevealing) and concern for regional or global
tamponade still exists. When the cause of tamponade is
a pneumothorax, a chest tube needs to be inserted emer-
gently after needle decompression if the patient has
hypotension and shortness of breath.
Arrhythmias
Patients may have atrial or ventricular arrhythmias or
atrial and ventricular arrhythmias. Atrial fibrillation and
atrial flutter have been reported to be present in patients
with LVADs and are associated with worse clinical out-
comes even without an increased risk of bleeding and
thromboembolism. Although rapid atrial arrhythmias
can be tolerated initially, loss of atrioventricular syn-
chrony results in reduced ventricular filling and decom-
pensated RV failure [20].
Rate control and anticoagulation are the primary goals
of therapy and restoring normal sinus rhythm is import-
ant. Antiarrhythmic therapies for long-term use include β-
blockers, such as metoprolol or sotalol, amiodarone, and
digoxin. Cardioversion may be beneficial if the arrhythmia
is of new onset. Radiofrequency catheter ablation has been
shown to be far superior to antiarrhythmic medications
for typical atrial fibrillation and atrial flutter, with cure
rates approaching 95 % and minimal risk of procedural
complications [20]. The frequency of arrhythmias may be
reduced by careful management of hemodynamic parame-
ters, volume status, and electrolyte balance.
Ventricular arrhythmias have been reported to occur
in 22 to 59 % of LVAD recipients [8, 21]. The presenta-
tion of ventricular arrhythmias in patients with LVADs
varies. Patients supported by LVADs may tolerate
ventricular arrhythmias with minimal symptoms and
stable hemodynamic parameters because of the LVAD’s
ability to maintain CO independent of heart rate and atrio-
ventricular synchrony [22]. However, ventricular arrhyth-
mias caused by impaired RV filling can lead to inadequate
LVAD flows and RV failure, hemodynamic deterioration,
and even cardiac arrest [21]. Most patients require an au-
tomated implantable cardioverter defibrillator (AICD) for
this reason and AICD shocks or overdrive antitachycardia
pacing can occur during episodes of ventricular arrhyth-
mias. Devices should be interrogated when patients have
palpitations, shortness of breath, or hypotension or when
the AICD fires. Reprogramming of the AICD may be
needed to avoid unnecessary or inappropriate shocks.
Uncontrollable ventricular arrhythmias can be an indica-
tion for temporary extracorporeal membrane oxygenation,
a BiVAD, heart transplantation, or a TAH. Intravenous
amiodarone and lidocaine can be administered for acute
symptoms. β-Blockers should only be used if patients do
not have overt cardiogenic shock or heart failure. Oral
amiodarone is often prescribed to suppress arrhythmias
for outpatients or for hospitalized patients after the acute
symptoms have been controlled with intravenous antiar-
rhythmic agents. For patients who cannot tolerate amio-
darone, sotalol can be an option. For patients taking any
of these medications, potassium and magnesium levels
should be closely monitored to ensure electrolyte bal-
ance and QT-prolonging medications should probably
be avoided.
Management of hemodynamic indices may reduce the
occurrence of arrhythmias. For example, suction events
may trigger ventricular arrhythmias; therefore, the de-
vice speed should be set to avoid excessive ventricular
unloading. This can be done by using echocardiography
to assess LV end-diastolic diameter and the degree of
aortic valve opening [23, 24]. Cardioversion and radio-
frequency ablation therapy after electrographic mapping
have also been described as therapeutic options for man-
aging arrhythmias [21].
Aortic valve degeneration
When used for extended periods, continuous-flow LVADs
can lead to aortic valve degeneration and aortic regurgita-
tion, as the alteration in blood-flow mechanics results in
increased load and mechanical stress on the valve. The
aortic valve leaflets can fuse either at the commissures or
at the midportion of the leaflet, creating an incompetent
valve [25, 26]. Such degeneration increases the risk of
thromboembolism, infection, congestive heart failure, and
cardiogenic shock. Aortic valve incompetence has been
reported in more than 90 % of patients undergoing long-
term ventricular assist device (VAD) support, although
the time course varies [18, 27]. Echocardiography should
be used to assess the status of the aortic valve.
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For patients with aortic valve incompetence, vasodilatory
antihypertensive agents should be prescribed to decrease
afterload. Before heart failure develops, valve replacement
or repair should be considered. In addition, the device
speed can be adjusted so that the aortic valve opens inter-
mittently, which will also improve hemodynamic indices
and delay aortic valve degeneration [28].
Device failure (HeartMate II)
Patients with an LVAD are dependent on the device for
their heart function and device failure may lead to circu-
latory arrest if the reason for the failure is not addressed
emergently. Emergency and critical care providers should
be aware of the critical steps associated with management
of device failure [29].
 Call the LVAD coordinator and coordinating center.
 Check the instruction booklet and color of the tag
on the system, which indicates the device type.
 Assess for battery alarms, advisory alarms, or hazard
alarms.
Battery alarm
In a low-battery state, the device defaults to a fixed-rate
mode of 8000 RPM (HeartMate II). The system will re-
turn to the set speed once adequate power is restored.
The simple fix is to replace the batteries or switch to an
alternative power source.
Advisory alarms
The yellow system driver signals low cell voltage and
beeps every 4 seconds. When this occurs, the cell battery
should be replaced and a system controller self-test per-
formed. The green advisory alarm signals a power-cable
disconnection; the power symbol and battery power bars
flash with beeps every second. Cable connections to the
power source should be checked and power leads should
be assessed for damage and replaced if necessary. The
red hazard alarm can indicate low flow and incorrect
operation, or both, which may suggest hypovolemia,
bleeding, tamponade, RV failure, hypertension, or ob-
struction of the cannulas. In these cases, both the pa-
tient and the device should be assessed emergently. The
hazard alarm can also indicate that the driveline is dis-
connected from the controller, so the connections need
to be checked. If there is a steady tone and no symbol,
there is no power to the device. All connections should
be checked immediately, e.g., the system driver connec-
tions to the device and the system driver and the power
connections to the power source. In these circum-
stances, patients may be at risk of cardiopulmonary ar-
rest because of minimal reserve in the cardiovascular
system.
Driveline damage
The driveline can fail in the course of normal wear. When
the driveline fails, a surgical procedure will often be re-
quired to replace it. Damage to the driveline wires may
occur inside the abdomen where the damage is not access-
ible to visual inspection. When damage occurs externally,
the outer silicone sheath may mask the damage to the
driveline wires. The most typical clinical findings associated
with driveline failure are the red heart alarm and a drop in
the pump speed below the auto-speed–low set limit. Radi-
ography showing driveline kinking or fraying in patients
with unexplained alterations in LVAD performance sug-
gests driveline damage and requires surgical management
[30]. In some cases, minimally invasive procedures to repair
the driveline have been done with a special sleeve-expander
tool and expandable latex tubing to stabilize the driveline,
without requiring pump exchange [31]. For patients who
present to the ED in circulatory arrest, individual stripping
and reconnection of the color-coded driveline wires using
hemostats, electric tape, and cardboard has been successful,
with reinstitution of flow from the LVAD [32].
Cannula obstruction
Obstruction of a cannula can also cause low device flow,
even with adequate volume. In some instances, the can-
nula is not positioned properly. For example, when the
inflow of the cannula points toward the septum or LV
free wall (rather than toward the mitral valve), it can be-
come intermittently blocked by septal shift. When a
cannula is obstructed, there will be reduced power con-
sumption and the VAD may make a chattering noise as
it tries to fill. When echocardiography is not sufficient
to make the diagnosis, patients may need to undergo CT
angiography, ventriculography (with intravascular ultra-
sound), or both in the cardiac catheterization laboratory.
Often an obstructed cannula must be surgically repaired,
although balloon angioplasty with stenting of the out-
flow graft is a possible nonsurgical option [33].
Device thrombosis
One of the common causes of a low CO state is device
thrombosis, which occurs in approximately 8 % of im-
planted, continuous-flow LVADs [34]. Device thrombosis
can obstruct inflow or outflow and can also interfere
with the motor. The thrombosis can originate within the
device but can also result from a thrombus elsewhere
being pulled into the LVAD [35]. Device thrombosis can
develop even when patients are fully anticoagulated and
taking antiplatelet therapy because the LVAD causes a
chronic hypercoagulable state. A low or therapeutic
international normalized ratio alone is not a good indi-
cator of device thrombus formation [36]. Predisposing
factors include blood–device surface interactions, shear
stress of blood flow because of altered blood-flow
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dynamics (continuous flow), cannula malposition, ac-
quired von Willebrand factor deficiency, and heparin-
induced thrombocytopenia [37].
Patients with a thrombosed device may have signs of
cardiogenic shock, including shortness of breath, hypo-
tension, and tachycardia. On auscultation, there may be
scratchy, grating, and rough sounds that are caused by de-
vice thrombus. In addition, there can be power spikes and
low-flow alarms from the device and an increased native
PI from the aortic valve’s opening or a significantly in-
creased pulse pressure. Results of laboratory tests that re-
veal evidence of hemolysis (lactase dehydrogenase [LDH]
levels greater than three times the upper limit of normal,
plasma free hemoglobin >40 mg/dL, or both) should raise
concern for possible thrombus. A plain chest radiograph
may show malposition of the inflow cannula, a misaligned
outflow graft, or pulmonary vascular congestion suggest-
ive of heart failure and echocardiography can document
signs of suboptimal LV unloading, including a dilated ven-
tricle, severe mitral regurgitation, and frequent aortic
valve opening or elevated RV systolic pressure or both.
Serial recording of LV end-diastolic diameter with increas-
ing VAD speeds (ramp study) may diagnose device
thrombus or other obstructions to blood flow within the
rotary pump and cannula system [38]. A filling defect in
the inflow or outflow cannulas can also be visualized on
CT angiography [39].
Patients with an LVAD that has developed thrombosis
will develop LV dysfunction and, ultimately, cardiogenic
shock and will need increased anticoagulant medications,
thrombolytic therapy, or a device exchange. To stabilize or
lower the LDH, the target value for the international nor-
malized ratio can be increased and aspirin (325 mg) or a
second antiplatelet agent, or both, can be considered. Epti-
fibatide, a glycoprotein IIb/IIIa inhibitor, has been used to
inhibit platelet aggregation but it has led to increased risk
of bleeding [40]. Thrombolytic therapy has also been used
successfully [15, 18, 41]. If other measures fail, device ex-
change or urgent transplantation may be considered [13].
The cornerstones of treatment for heparin-induced throm-
bocytopenia are discontinuation of heparin and use of al-
ternative anticoagulant agents, such as factor Xa inhibitors
(e.g., fondaparinux) and direct thrombin inhibitors (e.g.,
bivalirudin and argatroban) [42, 43].
Anemia
Anemia is common in patients with LVADs and may be
a result of an episode of acute bleeding or hemolysis or
may be chronic and associated with heart failure or nu-
tritional or iron deficiencies.
Bleeding
When bleeding is suspected, the source should be deter-
mined. A complete blood count, coagulation profile, and
type and screen should be ordered. Any coagulopathy
should be corrected and a blood transfusion may be re-
quired. Platelets should be given to patients taking as-
pirin and fresh frozen plasma and vitamin K should be
given to patients taking warfarin. Desmopressin may be
used if the patient is uremic. Angiographic approaches
to stop bleeding, e.g., retroperitoneal or gastrointestinal,
should be explored. Prothrombin complex concentrate
and factor VII should be considered as a last resort and
only if the patient is in hemorrhagic shock. This is par-
ticularly important because the risk of device thrombosis
is very high when these agents are used.
Hemoptysis
A variety of conditions can cause hemoptysis, including
RV failure, coagulopathy (anticoagulant-related), thrombo-
cytopenia, liver dysfunction, disseminated intravascular
coagulation, bronchitis, airway trauma, a foreign body,
and infection. An arteriobronchial fistula of the outflow
graft, which caused hemoptysis, has also been reported
[44]. When patients have hemoptysis, other causes of
acute bleeding (both external and internal) should be
ruled out. If there are no signs of external bleeding, bleed-
ing needs to be ruled out in the intracranial, intrathoracic,
intraabdominal, and pelvic compartments, and muscle
compartments of the extremities.
Hemolysis
In recent years, hemolysis has become an increasingly
recognized complication of LVAD support, with a preva-
lence of 0.5 to 18 % [45]. Hemolysis after LVAD implant-
ation is associated with an extremely high 1-year
mortality that is more than two times greater than that
observed for patients (HeartMate II) who do not have
hemolysis [45]. Increased shear stress on red blood cells
as they pass through the device is the main mechanism
for hemolysis and is usually caused by malpositioning or
migration of the device cannula; kinking or pannus on
the outflow cannula and graft thrombus formation
within the pump, on the inlet and outlet stators (but not
the rotor); or aortic insufficiency [46]. Patients can also
have anemia without bleeding, which is accompanied by
increased bilirubin, LDH, and plasma free hemoglobin
levels and an undetectable haptoglobin level.
The role of imaging in determining the cause of
hemolysis is unclear. TEE may be beneficial for assessing
cannula velocities. Computed tomographic imaging may
be helpful for diagnosing a mechanical inflow cannula
obstruction.
Treating hemolysis can be challenging. The device
speed may need to be adjusted downward. Glycoprotein
IIb/IIIa inhibitors have also been used [47]. When this
type of antiplatelet therapy is not tolerated, pentoxifylline
has been used to improve blood flow. Plasmapheresis has
Sen et al. Critical Care  (2016) 20:153 Page 10 of 20
also been undertaken with some success. The definitive
therapy is device exchange if no reversible cause of
hemolysis is identified.
Chest pain
Chest pain in patients with LVADs is a complex issue
but is most commonly due to noncardiac causes [12].
The true incidence of ischemic chest pain during LVAD
support remains unknown.
Cardiac causes of chest pain include acute MI, unstable
angina, pericarditis, myocarditis, and aortic dissection.
Management of a new MI has been described above. Aor-
tic dissection has been reported in patients undergoing
LVAD support, especially those with the pulsatile Novacor
device (WorldHeart Corp.) [48] and the HeartMate XVE
(Thoratec Corp) device in the postoperative phase [49].
However, these devices are now essentially obsolete. TEE
is used to identify aortic dissection. Sometimes the com-
petition of the retrograde pump flow and the anterograde
native blood flow may give an impression of an aortic dis-
section on CT angiography and TEE, which can be re-
solved by lowering the pump speed [50, 51].
Other noncardiac causes of chest pain in a patient
with an LVAD are pulmonary embolus, which is rare
[52], pneumothorax, esophageal tear, cholecystitis, pan-
creatitis, pneumonia and pleuritis, pneumomediastinum,
esophageal spasm, gastroesophageal reflux disease, pep-
tic ulcer disease, biliary colic, costochondritis, rib injury
or fracture, arthritis, spinal root compression, or post-
herpetic neuralgia.
Syncope
Syncope can be cardiac in origin, caused by hypotension
(all causes of low CO as above), arrhythmias, or aortic
valve thrombosis [53], or it can be noncardiac in origin.
Trauma, GI bleeding, rupture of an aortic aneurysm, a
ruptured ovarian cyst, or a ruptured spleen decrease ef-
fective blood volume and, thus, can lead to syncope.
Other causes are hypoxemia, pulmonary embolism, sub-
arachnoid hemorrhage, vertebrobasilar transient ischemic
attack, subclavian steal syndrome, and neurocardiogenic
syncope. Pregnancy has been reported in patients with
LVADs; therefore, for young women, ectopic pregnancy
should be ruled out as a cause of syncope [54]. Orthostatic
left atrial and LV chamber collapse have been reported
after postural change [55]. Fludrocortisone and midodrine
have been used to treat syncope. Ruling out seizures is
necessary.
A variety of means can be used to determine the cause
of the syncope. A detailed physical examination and de-
vice interrogation should be performed. Laboratory tests
to consider include a complete blood count, an electro-
lyte and metabolic panel, serum glucose evaluation, co-
agulation panel, arterial blood gas values, lactate levels,
urinalysis, urine drug screen, and blood and urine cul-
tures (if syncope and hypotension with sepsis or septic
shock are differential diagnoses). Electrocardiography
and AICD interrogation are valuable. Echocardiography
can be used to assess the possibility of tamponade, RV
dysfunction, aortic valve opening, and thrombosis. CT of
the head should be done with a low threshold as patients
are usually taking anticoagulants. A CT scan can also be
used to rule out pulmonary embolism and aortic dissec-
tion. All patients with syncope should be considered for
hospital admission.
Gastrointestinal issues
The LVAD-related causes of GI symptoms are GI bleed-
ing, hemolysis, hepatitis, pancreatitis, hepatic dysfunc-
tion, mesenteric ischemia or infarction, MI, pneumonia,
pulmonary embolism, uremia, electrolyte abnormalities,
neurologic causes like hypoperfusion and intracranial
bleeding, low CO states, sepsis, and prescribed drugs.
Gastroenteritis, diverticulitis, appendicitis, viscus perfor-
ation, small bowel obstruction, biliary tract disease, ur-
eteral colic, urinary tract infection, diabetic ketoacidosis,
herpes zoster, muscle spasm, and pregnancy are non-
LVAD-related causes of nonspecific GI symptoms.
Dysphagia
Intravascular hemolysis has been linked to smooth muscle
dystonia, which results in dysphagia and abdominal pain in
patients with LVADs. An excessive level of plasma free
hemoglobin can result in dystonia of the GI system [56, 57]
and could indicate ongoing hemolysis. Symptoms should
subside with such therapies as intravenous tissue plasmino-
gen activator, pump exchange, or both.
GI bleeding
The incidence of GI bleeding in LVAD patients has been
reported to be approximately 22 to 40 % [58]. The cause
of the bleeding is thought to be due to the altered
blood-flow patterns of continuous flow and also to ac-
quired von Willebrand factor deficiency [59]. The min-
imal opening of the aortic valve creates flow patterns
similar to that in patients with aortic stenosis (called
Heyde syndrome), which leads to abnormal pulse waves,
intestinal hypoperfusion, and distension of the submuco-
sal venous plexuses of the GI tract. This, in turn, leads
to angiodysplasia, arteriovenous malformations, and
bleeding—eventually with minimal shear stress. Another
possible mechanism of GI bleeding in these patients is
acquired von Willebrand disease type 2A, which is
caused by a deficiency of high molecular weight multi-
mers of von Willebrand factor. This deficiency can occur
in patients with continuous-flow LVADs secondary to
shear stress on red blood cells [60, 61]. In addition, the
contact between blood and the foreign surfaces of the
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LVADs may alter the rheology of blood flow, leading to
a state of compensated coagulopathy. This process does
not continue after cardiac transplantation. Gastric antral
vascular ectasia (GAVE) syndrome is another rare cause
of GI bleeding in patients with an LVAD. On endoscopy,
the typical pathognomonic patterns seen for GAVE are
red spots organized in stripes radiating from the pylorus
(often described as watermelon stomach and usually seen
in patients without cirrhosis) or arranged in a diffusely
punctuated manner (the so-called honeycomb stomach,
which is more common in cirrhosis) [62, 63].
In a few cases, octreotide, a long-acting somatostatin
analog that decreases splanchnic arterial and portal
blood flow, has been used to treat GI bleeding [64, 65].
The patients treated with octreotide for chronically
bleeding arteriovenous malformations had fewer hospital
admissions and administered blood units and had mean
hemoglobin values that were higher than would be typ-
ical for patients with this condition.
An algorithm for diagnostic and therapeutic approaches
to patients with GI bleeding is summarized in Fig. 5.
Acute kidney injury
Oliguria and anuria
Patients may present with a new onset of acute kidney
injury (AKI). They may report oliguria, abdominal pain,
fatigue, nausea, vomiting, dysuria, hematuria, and lower
extremity edema. The incidence of AKI after LVAD im-
plantation has been reported to range from 7 to 56 %
[66], with the large variation in range likely due to differ-
ing definitions for AKI, the extent of heart failure, and
the severity of preexisting kidney disease [66]. Most
patients have improved kidney function after device
implantation. The mortality rate is high for those pa-
tients who develop AKI after LVAD implantation.
Figure 6 shows the possible causes of AKI in patients
who have an LVAD. Poor forward flow due to device
malfunction or LV dysfunction, as well as pigment ne-
phropathy from hemolysis, is important in the process
of differential diagnosis. The diagnostic approach to AKI
is also summarized in Fig. 6. Patients who do not im-
prove after optimizing hemodynamic parameters and
volume status may need renal replacement therapy. Cri-
teria for renal replacement therapy are the same for pa-
tients with or without LVADs, i.e., acidosis, electrolyte
imbalance (hyperkalemia, hyperphosphatemia), fluid over-
load, and uremic encephalopathy and pericarditis. Emer-
gency dialysis will require temporary catheter placement.
For long-term hemodialysis, arteriovenous graft placement
is preferred to avoid the high risk of infection associated
with central venous catheters. Although there are no stud-
ies that describe maturation of arteriovenous fistulas in
patients with LVADs, theoretical considerations of non-
pulsatile flow have led authors to believe that an arterio-
venous fistula should not be considered a vascular access
option [66]. Peritoneal dialysis can also be used with the
newer VADs, which are implanted in the precordial
space or preperitoneal space behind the rectus sheath.
Doppler audible ultrasonography should be used to
assess arteriovenous-graft patency.
Hematuria
Hematuria in a patient with an LVAD could be either
VAD-related or non-VAD-related. Intravascular hemo-
lysis (hemoglobinuria), rhabdomyolysis, anticoagulation,
medication-induced thrombotic thrombocytopenic purpura,
Fig. 5 Gastrointestinal bleeding in patients with mechanical cardiac assist devices. AVM arteriovenous malformation, GAVE gastric antral vascular
ectasia, GI gastrointestinal, INR international normalized ratio, PPI proton pump inhibitor, RFA radiofrequency ablation, VAD ventricular assist device
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and bacterial endocarditis are VAD-related causes of
hematuria. Drugs, urinary tract infection, nephrolithiasis,
benign prostatic hyperplasia, prostate, bladder, and renal
malignancies, and autoimmune diseases are non-VAD-
related causes of hematuria.
The following laboratory and imaging tests should be
ordered to determine the cause of the hematuria: urin-
alysis; urine culture; plasma free hemoglobin, LDH, and
haptoglobin levels; coagulation panel, ADAMTS13 activ-
ity and inhibitor profile (if thrombotic thrombocytopenic
purpura is a consideration); renal function panel; urine
eosinophil level; ultrasonography of the kidneys or CT
imaging; and cystoscopy. A urology consultation may
also be considered.
Infection
Continuous-flow LVADs have lower overall infection
rates compared with pulsatile devices but the rates still
range from 30 to 50 % in patients with implanted de-
vices [67, 68]. Patients who undergo LVAD implantation
for destination therapy are more likely to develop infec-
tions than patients who had LVADs implanted as a
Fig. 6 Diagnostic and management approach to patients with acute kidney injuries. ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin
receptor blockers, NSAID nonsteroidal anti-inflammatory drug
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bridge to transplantation because destination therapy pa-
tients tend to be sicker and have longer durations of
LVAD support.
The diagnosis of sepsis in patients with LVADs is the
same as that for other patient populations. Important
steps in the management of sepsis include blood cul-
tures, antibiotics, measuring lactate levels to assess for a
state of vasodilatory shock and reduced tissue perfusion,
and intravenous fluids, as deemed necessary based on
the hemodynamic assessment. Patients may be hypo-
tensive and have vasodilatation, with high VAD flow
rates. Therefore, vasopressor agents may be needed early
in the management course. Central access and measure-
ment of central venous pressure for assessment of fluid
responsiveness may help in guiding therapy. Inotropic
agents may be needed if septic cardiomyopathy leads to
RV dysfunction. VADs are related directly or indirectly
to a variety of infections, including the VAD-specific in-
fections (pump pocket, cannula, driveline) and VAD-
related infections (endocarditis and pericarditis). VAD
patients are also susceptible to mediastinitis and pneu-
monia, central line infections, e.g., a PICC line (peripher-
ally inserted central catheter), or other non-VAD-related
infections, such as urinary tract infections. Meticulous
head-to-toe assessment is necessary to consider all pos-
sible sources of infection in patients who meet sepsis
criteria [68, 69].
Driveline infections
Driveline infections occur in 17 to 30 % of patients with
LVADs [68]. Cutaneous migration of bacteria and local
trauma are causative factors and there may be cellulitis
at the exit site. Ultrasonography and CT may be helpful
for evaluating the condition of the driveline. Commonly
seen organisms include species of Staphylococcus, En-
terococcus, Pseudomonas, Enterobacter, and Candida.
Oral or intravenous antibiotics should be administered
according to the severity of the infection. Two weeks of
therapy may suffice, although prolonged treatment may
be necessary when the patient has bacteremia.
Pump-pocket infection
Pump-pocket infections occur in 2 to 10 % of patients
with LVADs [68]. These infections may appear as an ab-
scess beneath the skin or there may be purulent drainage
and systemic signs (e.g., sepsis). Ultrasonography and
computed tomography can be used in the diagnosis of
pump-pocket infections. Staphylococcus species is a
common cause; Gram-negative bacteria and Candida
species have also been reported. Management includes
drainage and debridement of the device pocket and em-
piric, broad-spectrum antibiotics. Long-term antimicro-
bial suppressive therapy may be indicated. Wrapping the
omentum has been described to help prevent pocket in-
fections [68].
Cannula or endocarditis (device) infection
Although rare (approximately 0.6 %) [68], infection occur-
ring in the device or a cannula is associated with a high
mortality. Diagnosis is usually presumptive when other
sources of infection cannot be found and patients gener-
ally present with septic shock. Device removal is necessary
and urgent transplantation is the preferred treatment for
bridge-to-transplant patients. Chronic antibiotics may be
necessary for destination-therapy patients.
Bloodstream infection
Bloodstream infections are common, with a reported
rate of 20 to 27 % [68]. Patients with bloodstream infec-
tions can have fever, leukocytosis, septic shock, and sep-
tic embolization, which may emanate from the central
catheter or be LVAD-related. If blood cultures from a
peripheral and central catheter grow the same organism
less than 2 h apart, this is usually a sign of LVAD-related
bacteremia. More than 2 h between the two cultures
could indicate a catheter-related infection. Empiric anti-
biotics should be given and the central catheter should
be removed. If the bacteremia continues, the device
should be exchanged or a heart transplant done, al-
though both of these procedures are associated with a
low survival rate [68].
Other possible sources of infection are pneumonia,
urinary tract infections, sinusitis, cholecystitis, wound
infections, and cellulitis.
Neurologic symptoms
The initial assessment of an LVAD patient with altered
mental status or new-onset focal or global neurologic
deficits should be similar to that done for any patient
with this condition and should include a primary survey
and an assessment of the device. The LVAD coordinator
and the cardiac surgery team should be contacted.
Causes of altered mental status and confusion could be
related to low-flow states and hypotension, stroke,
seizure, infections, medications, electrolyte or metabolic
abnormalities, hypoxia, hypercarbia or trauma, and throm-
boembolic causes. In addition to routine workup for the
above, a complete blood count, a hemolysis panel (LDH/
haptoglobin, bilirubin, and plasma free hemoglobin levels),
and a coagulation panel should be ordered.
With the introduction of continuous-flow devices, the
incidence of stroke in patients with LVADs has de-
creased substantially; however, patients remain at a high
risk for stroke [70]. Of the neurologic events associated
with LVADs, ischemic stroke is most prevalent but
hemorrhagic stroke has a higher mortality rate [71]. A
study comparing the use of pulsatile-flow LVADs and
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continuous-flow LVADs showed the rate of hemorrhagic
stroke to be 11 % in the continuous-flow group and 8 %
in the pulsatile-flow group [72]. Risk factors for ischemic
stroke in patients with LVADs include diabetes, having
had a previous stroke, aortic cross-clamping with cardio-
plegic arrest during the LVAD implantation procedure
[73], and systemic infection [74].
Neurologic events in patients with LVADs are gener-
ally related to several factors. First, patients with LVADs
take anticoagulation and antiplatelet medications chron-
ically to prevent thrombosis in the device. No universally
accepted protocol exists for anticoagulation and anti-
platelet therapy after LVAD insertion, although most
regimens include postoperative heparin with a transition
to warfarin, aspirin, and potentially dipyridamole or clo-
pidogrel [75]. The need for anticoagulation predisposes
these patients to intracranial hemorrhage and hemor-
rhagic stroke, as well as to other sequelae related to
bleeding [75]. Second, LVAD patients can develop ac-
quired von Willebrand syndrome, as described above,
which seems to be related to the shear stress the device
exerts and to impaired hemostasis of the vascular endo-
thelium. Third, infection is also associated with stroke.
Fourth, device thrombosis from a source outside the
LVAD or formed within the device is a well-known cause
of embolic stroke in patients. Of all strokes that oc-
curred, 58 % were found to occur in the right hemi-
sphere, 28 % in the left hemisphere, and 6.5 % in both
hemispheres. In addition, about 6.5 % of strokes are ver-
tebrobasilar in origin [76]. The predilection for right
hemispheric stroke was explained by the anatomic align-
ment directing thrombotic material toward the brachio-
cephalic trunk [76].
Protocols exist for the acute management of stroke in
LVAD patients [77] and begin with contacting the neur-
ology team. Anticoagulation therapy should be consid-
ered for patients with ischemic stroke and coagulopathy
needs to be reversed for patients with hemorrhagic
stroke. The most common approaches for managing
stroke follow.
Ischemic stroke
CT and CT angiography should be used to determine
the cause and extent of ischemic stroke. The risks and
benefits of systemic thrombolytic agents need to be dis-
cussed among the cardiology, cardiac surgery, neurology,
and critical care teams. If there is a large-vessel occlu-
sion, an endovascular procedure can be considered.
Hemorrhagic stroke
If a patient has been taking warfarin, prothrombin com-
plex concentrate or fresh frozen plasma should be ad-
ministered. Vitamin K can also be given. Desmopressin
and a platelet transfusion should be considered for those
patients taking antiplatelet drugs. If systemic thrombo-
lytic therapy has been administered and an intracranial
hemorrhage is noted subsequently, cryoprecipitate and
antifibrinolytic agents, such as ε-aminocaproic acid or
tranexamic acid, should be considered.
Headache
Headaches have several possible causes. Central nervous
system causes include intracranial hemorrhage and re-
versible posterior leukoencephalopathy syndrome [78].
Cardiopulmonary causes include hypoxic and hypercar-
bic respiratory failure, low CO, and hypertension. Al-
though primary central nervous system infections are
rare, secondary seeding from bloodstream infections and
endocarditis may occur and should be investigated.
Other causes of headache unrelated to the LVAD include
medications, migraine headache, toothache, eye pain, si-
nusitis, and musculoskeletal pain.
Back pain
Causes of back pain that are VAD-related include epidural
hematoma, abscess, retroperitoneal bleeding, aortic dis-
section, and pulmonary embolism. Non-VAD specific rea-
sons for back pain include cauda equina, spinal fracture,
disk herniation, osteoarthritis, osteomyelitis, spinal sten-
osis, and muscle sprain. Other causes include cholecystitis,
pancreatitis, peptic ulcer diseases, nephrolithiasis, ovarian
torsion, pulmonary embolism, pneumonia, and tumors.
Brain death and organ donation
Neurologic events during LVAD support are associated
with significant morbidity and mortality rates and can
cause brainstem death. A patient with diagnosed brain
death who is supported by a VAD and has preserved
end-organ function can and should be considered for
donating organs [79], including the liver, kidneys, and
lungs. In some cases, organ donation has also occurred
after cardiac death.
Cardiac arrest
Cardiac arrest may occur in patients whose circulation is
supported by an LVAD. In these cases, a stepwise ap-
proach to management should be used. The VAD coord-
inator should be contacted immediately. All of the VAD
equipment should be assessed to verify that critical con-
nections are intact. The driveline and power supply
should be checked and reconnected if disconnected.
Alarms should be assessed. If there is a VAD hum, it
should be assessed with auscultation. Doppler ultrason-
ography should be used to evaluate the patient’s blood
pressure. If the pump is off, the backup controller
should be switched on or, alternatively, the power
sources should be switched. Advanced cardiac life sup-
port should be continued without chest compression.
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(Although chest compression was not reported as harm-
ful in a case series [80], the current recommendation is
for no chest compression.) The major risk associated
with chest compression during cardiopulmonary resusci-
tation is dislodgement of the device or its outflow can-
nula, which is located directly beneath the sternum. A
potential alternative to chest compression is abdominal
compression 1 to 2 inches left of midline, which has
been described [81] but is not currently recommended.
Other than that noted above, management is done per
advanced cardiac life support guidelines and includes
the use of epinephrine and cardioversion.
Orthopedic injuries
Fractures may require operative fixation. Because of the
possibility of fat embolism during the intraoperative and
postoperative periods and subsequent RV failure, pa-
tients with LVADs should be monitored closely. Trans-
cranial Doppler ultrasonography can be used to help
monitor cerebral perfusion.
Psychiatric and pyschological issues
Patients with LVADs may have psychiatric and psycho-
logical issues [82], such as depression, anxiety, paranoid
ideation, sleep disturbances, somatization, psychosis, and
obsessive-compulsive behavior. Some of these issues
may have existed before device implantation because of
the stress and effects of chronic heart failure and re-
duced perfusion to the brain. Insertion of an LVAD is re-
ported to improve neurocognitive symptoms, including
substantial improvements in memory in advanced heart
failure patients [83]. However, acute psychiatric or psy-
chological presentations in patients with LVADs should
be investigated for organic causes like thrombosis, new
stroke, and seizures. Monitoring a patient’s cognitive sta-
tus is necessary to maximize the benefits of therapy and
enhance quality of life.
Noncardiac surgery
Noncardiac surgery can be accomplished safely while pa-
tients are being supported with a mechanical circulatory
assist device. In a case series, 20 patients underwent 25
noncardiac, nonlaparoscopic surgical operations, includ-
ing repair of inguinal hernia, cholecystectomy, small- and
large-bowel surgery, and other gynecologic procedures;
there were few complications and no deaths [84]. Bleeding
requiring blood transfusion and operative reexploration
was the most serious complication. However, it occurred
less often in patients who discontinued taking warfarin be-
fore the operation. Other reports have described the rela-
tive safety of discontinuing warfarin in patients with a
contraindication to anticoagulation and an implanted
LVAD [85, 86]. Therefore, warfarin can be discontinued
for 5 days before a major operative procedure to reduce
the risk of postoperative bleeding [84]. In addition, hep-
arin can be used as a bridge for those patients who need
anticoagulation therapy because of atrial fibrillation or LV
thrombus [84]. Fresh frozen plasma and vitamin K can be
used to rapidly reverse the anticoagulation therapy when
an emergency operation is needed for a patient with an
implanted device; this has been done without an increased
incidence of device thrombosis.
Trauma
When a patient with an LVAD presents with trauma, de-
vice malfunction needs to be assessed immediately (as de-
scribed above), including by radiography and CT, if
necessary. Advanced Trauma Life Support guidelines
(American College of Surgeons) should be followed to rule
out traumatic subarachnoid hemorrhage or subdural
hematoma, pneumothorax, hemothorax, pulmonary injur-
ies, intraabdominal organ injuries, and spinal cord trauma.
The VAD coordinator and CT surgery team should be
contacted. Trauma-related failure of a continuous-flow
LVAD has been reported [87]. Damage to the cables and
displacement of the pump from its original position hap-
pened after patients fell or were hit in the chest.
Biventricular assist devices
The incidence of RV failure requiring an RVAD has de-
creased with the transition to continuous-flow devices
[88–90]. Only 4 % of patients in the HeartMate II BTT
trial required RVAD support [71]. In addition, risk-
assessment tools have been developed to help determine
which patients might need BiVAD support [91, 92].
Biventricular support is more complicated to manage
and, to avoid pulmonary edema, LV output must always
be greater than RV output [93]. Native RV and LV func-
tion may also recover at different rates.
Two devices are used for BiVAD support: the Thoratec
PVAD/IVAD (Thoratec Corp.) and the HeartWare. The
PVAD/IVAD system provides pulsatile flow and the
HeartWare (as described previously) provides continu-
ous flow [88, 89]. The PVAD system has three main
components: a blood pump, cannulas, and a pneumatic
driver (Dual Drive Console or TLC-II Portable VAD
Driver). The Thoratec IVAD is an implantable version of
the Thoratec PVAD. Simultaneous LV and RV support
using dual HeartWare pumps is common but the inci-
dence of right-sided HVAD pump thrombosis is high.
To maintain lower flows in the pulmonary system, apart
from controlling speeds, a pinched valve or smaller-
diameter outflow graft [88, 90] have been reported for
use on the right side. The mortality rate for patients
undergoing BiVAD support increases as the length of
time on biventricular support increases. The HeartMate
3, currently undergoing clinical trials (MOMENTUM 3),
may also be used eventually for BiVAD support.
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A few reports in the literature describe experiences in
discharging a small number of BiVAD patients home to
await transplantation [62, 94, 95]. The three leading
causes of readmissions in one study were GI bleeding
(23 %), pulsatile ventricular assist device (PVAD) throm-
bosis (17 %), and infections at the site of VAD placement
(15 %), which were consistent with complication rates
from other studies after VAD implantation [95]. Man-
aging treatment with a BiVAD is similar to managing
treatment with an LVAD, although the RV and LV out-
put can be pulsatile or continuous, depending on the de-
vice used.
Total artificial heart
The TAH is designed to replace the cardiac structures
completely and to provide long-term support as a BTT. A
TAH is considered for those patients in whom biventricu-
lar support is required. The SynCardia TAH (formerly
called CardioWest; SynCardia Systems, Inc.) is a biventri-
cular pneumatic pulsatile pump that replaces the native
ventricle and all four heart valves [96]. The SynCardia
TAH has been approved by the US Food and Drug Ad-
ministration (FDA) as a BTT and received a recent ap-
proval from the FDA for a clinical study of effectiveness
for destination therapy. The two pumps are placed in the
orthotopic position after polyurethane inflow connectors
are sutured to the left and right atrial cuffs of the recipient
[97]. Dacron outflow grafts connect the TAH to the pul-
monary artery and aorta. A percutaneous driveline con-
nects to the system controller (either the pneumatic
Freedom portable driver [SynCardia Systems, Inc.] or the
nonportable hospital driver [often called Big Blue]). The
device will pump up to 9.5 L/min through both ventricles;
blood is pumped by the action of internal, pneumatically
driven diaphragms. The design of the TAH (partial fill and
full eject) allows for a more physiologic response, i.e., the
TAH accepts and pumps blood on the basis of the pa-
tient’s need—either at rest or exercise—without requiring
an adjustment for heart rate [97]. Thus, the device settings
are patient-specific, based on the afterload pressures of
the aorta and pulmonary artery [97, 98].
The adverse events that occur with TAH support are
similar to those in patients with LVADs. Respiratory fail-
ure, infections, bleeding, anemia, hemolysis, neurologic
events, hepatic dysfunction, peripheral thromboembol-
ism, and renal failure may occur. It is important to re-
member that patients with an implanted TAH will have
a pulse, whereas patients with an LVAD usually will not
have a pulse. Patients with a TAH will not have a cardiac
rhythm, whereas patients with an LVAD will have a car-
diac rhythm. For patients with a TAH, a pressure cuff is
all that is needed for monitoring. CO and filling volume
of the right- and left-sided pumps should be assessed
frequently. Cardiopulmonary resuscitation is ineffective
for TAH patients and inotropic agents will not change
hemodynamic parameters.
Three types of alarms can occur: (1) a battery alarm,
(2) a temperature alarm, and (3) a fault alarm [29]. Bat-
teries should be replaced one at a time and reinstalled
correctly. The temperature alarm indicates the internal
temperature of the driver is too hot or the temperature
of the onboard batteries is too hot. In this case, any ob-
jects that are blocking the filter cover, fan, or both
should be removed. The filter cover should be inspected
or the Freedom portable driver should be moved to a
cooler area. A fault alarm can indicate a Valsalva maneu-
ver, a kinked or disconnected driveline, a driver that is
connected to external power without at least one cor-
rectly inserted onboard battery or a battery with less
than 30 % charge, and malfunction of the driver. These
possible problems should be considered to address the
alarm. A backup Freedom portable driver should be
available in the case of driver malfunction.
Conclusions
Current, continuous-flow mechanical circulatory assist
devices are smaller, more durable, safer, and more effect-
ive for treating patients with severe heart failure than
their pulsatile-flow predecessors. With the FDA’s market
approval of the HeartMate II, more patients are having
these devices implanted, and additional devices are cur-
rently undergoing clinical trials. Thus, health care pro-
viders in EDs and ICUs need to have a good knowledge
of the symptoms and signs associated with complica-
tions of these devices and be able to make the differen-
tial diagnosis and begin the management steps required
for a successful outcome for these patients. A multidis-
ciplinary team-based approach is the first essential step
to improved patient outcomes.
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